Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020
| العنوان: | Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020 |
|---|---|
| المؤلفون: | Jaap Seelig, J. R. de Groot, Frans H. Rutten, Gordon Chu, Menno V. Huisman, Martin E.W. Hemels, Emmy M. Trinks-Roerdink, Geert-Jan Geersing |
| المصدر: | Netherlands Heart Journal, 28, 19-24 Netherlands Heart Journal, 28, Suppl 1, pp. 19-24 Netherlands Heart Journal Netherlands Heart Journal, 28(SUPPL 1), 19-24. BOHN STAFLEU VAN LOGHUM BV |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Stroke and bleeding risk, Registry, medicine.medical_specialty, medicine.drug_class, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Review Article, 030204 cardiovascular system & hematology, WARFARIN, RISK STRATIFICATION, Anticoagulation, 03 medical and health sciences, 0302 clinical medicine, BLEEDING RISK, SCORE, Antithrombotic, medicine, 030212 general & internal medicine, Dosing, Intensive care medicine, Stroke, ORAL ANTICOAGULANTS, CHA(2)DS(2)-VASC, business.industry, PERSISTENCE, Anticoagulant, DABIGATRAN, RIVAROXABAN, Integrated care, Atrial fibrillation, medicine.disease, Adherence, Stroke prevention, STROKE RISK, Cardiology and Cardiovascular Medicine, business, Risk assessment |
| الوصف: | Contains fulltext : 225355.pdf (Publisher’s version ) (Open Access) In recent years, as more and more experience has been gained with prescribing direct oral anticoagulants (DOACs), new research initiatives have emerged in the Netherlands to improve the safety and appropriateness of DOAC treatment for stroke prevention in patients with atrial fibrillation (AF). These initiatives address several contemporary unresolved issues, such as inappropriate dosing, non-adherence and the long-term management of DOAC treatment. Dutch initiatives have also contributed to the development and improvement of risk prediction models. Although fewer bleeding complications (notably intracranial bleeding) are in general seen with DOACs in comparison with vitamin K antagonists, to successfully identify patients with high bleeding risk and to tailor anticoagulant treatment accordingly to mitigate this increased bleeding risk, is one of the research aims of recent and future years. This review highlights contributions from the Netherlands that aim to address these unresolved issues regarding the anticoagulant management in AF in daily practice, and provides a narrative overview of contemporary stroke and bleeding risk assessment strategies. |
| وصف الملف: | application/pdf |
| تدمد: | 1568-5888 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8606e142ec0ec06dd3d6de3e28e3ef9bTest http://hdl.handle.net/2066/225355Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....8606e142ec0ec06dd3d6de3e28e3ef9b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15685888 |
|---|